Evidence map›Paper›PMID 38788675›Full record

ArticleJournal of the National Cancer Institute2024

Alzheimer disease-related biomarkers and cancer-related cognitive decline: the Thinking and Living with Cancer study.

Jeanne Mandelblatt, Jeffrey L Dage, Xingtao Zhou, Brent J Small, Tim A Ahles, Jaeil Ahn, Ashley Artese, Traci N Bethea, Elizabeth C Breen, Judith E Carroll and 18 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the National Cancer Institute, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Cancer treatment-related cognitive impairment.Neuro-oncology advances · 2026
    Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

28 authors.

Jeanne MandelblattGeorgetown Lombardi Institute for Cancer and Aging Research, Lombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University, Washington, DC, USA.ORCID 0000-0002-2490-005X
Jeffrey L DageStark Neurosciences Research Institute, Department of Neurology, Indiana University School of Medicine, Indianapolis, IN, USA.
Xingtao ZhouDepartment of Biostatistics, Bioinformatics, and Biomathematics, Georgetown University, Washington, DC, USA.ORCID 0000-0002-5164-125X
Brent J SmallSchool of Aging Studies, University of South Florida, and Health Outcomes and Behavior Program, Moffitt Cancer Center, Tampa, FL, USA.
Tim A AhlesDepartment of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Jaeil AhnDepartment of Biostatistics, Bioinformatics, and Biomathematics, Georgetown University, Washington, DC, USA.ORCID 0000-0001-7998-4759
Ashley ArteseDepartment of Exercise Science and Health Promotion, Charles E. Schmidt College of Science, Florida Atlantic University, Boca Raton, FL, USA.
Traci N BetheaLombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University, Washington, DC, USA.
Elizabeth C BreenSemel Institute for Neuroscience and Human Behavior, Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, CA, USA.
Judith E CarrollSemel Institute for Neuroscience and Human Behavior, Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, CA, USA.
Harvey J CohenDepartment of Medicine, Center for the Study of Aging and Human Development, Duke University Medical Center, Durham, NC, USA.
Martine ExtermannSenior Adult Oncology Program, Department of Oncology, Moffitt Cancer Center, University of South Florida, Tampa, FL, USA.ORCID 0000-0003-4381-1199
Deena GrahamJohn Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA.
Isaacs ClaudineLombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University, Washington, DC, USA.
Heather S L JimDepartment of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, USA.
Brenna C McDonaldDepartment of Radiology and Imaging Sciences, Melvin and Bren Simon Comprehensive Cancer Center, and Indiana Alzheimer's Disease Research Center, Indiana University School of Medicine, Indianapolis, IN, USA.
Zev M NakamuraDepartment of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Sunita K PatelDepartment of Population Sciences and Department of Supportive Care Medicine, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
G William RebeckDepartment of Neuroscience, Georgetown University, Washington, DC, USA.
Kelly E RentscherDepartment of Psychiatry and Behavioral Medicine, Medical College of Wisconsin Cancer Center, Medical College of Wisconsin, Milwaukee, WI, USA.
James C RootDepartment of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-7332-6165
Kristen A RussDepartment of Medical and Molecular Genetics and National Centralized Repository for Alzheimer's and Related Dementias, Indiana University School of Medicine, Indianapolis, IN, USA.
Danielle B TometichDepartment of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, USA.
R Scott TurnerDepartment of Neurology, Georgetown University, Washington, DC, USA.
Kathleen Van DykSemel Institute for Neuroscience and Human Behavior, Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, CA, USA.ORCID 0000-0003-1500-930X
Wanting ZhaiDepartment of Biostatistics, Bioinformatics, and Biomathematics, Georgetown University, Washington, DC, USA.
Li-Wen HuangDivision of Hematology/Oncology, University of California San Francisco and San Francisco Veterans Affairs Medical Center, San Francisco, CA, USA.
Andrew J SaykinDepartment of Radiology and Imaging Sciences, Melvin and Bren Simon Comprehensive Cancer Center, and Indiana Alzheimer's Disease Research Center, Indiana University School of Medicine, Indianapolis, IN, USA.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD)U24AG021886 · NIA · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI TATIANA M. FOROUD · 2002 to 2026
$119.8M
Tissue Culture Shared ResourceP30CA051008 · NCI · GEORGETOWN UNIVERSITY · PI MARCUS S NOEL · 1990 to 2026
$71.5M
Tumor Microenvironment and Metastasis ProgramP30CA082709 · NCI · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI David W Clapp · 1999 to 2026
$59.3M
Research Education ComponentP30AG010133 · NIA · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI SAYKIN, ANDREW J · 1991 to 2020
$37.3M
Training and Career Development and Education CoreU54CA137788 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Daniel Alan Heller · 2008 to 2026
$28.1M
Quality Assurance and Quality Control Project Management: Improving Submissions and Study Conduct in the Human Subjects Research Prior Approval ProcessUL1TR002529 · NCATS · INDIANA UNIVERSITY INDIANAPOLIS · PI MOE, SHARON M, WIEHE, SARAH ELIZABETH · 2018 to 2022
$27.2M
Resource Core 3 - Metabolomics CoreP30AG028716 · NIA · DUKE UNIVERSITY · PI CATHLEEN S COLON-EMERIC, Susan Nicole Hastings · 2006 to 2026
$24.6M
Research Education ComponentP30AG072976 · NIA · INDIANA UNIVERSITY INDIANAPOLIS · PI ANDREW J SAYKIN · 2021 to 2026
$24.1M
BEHAVIOR AND PHYSIOLOGY IN AGINGT32AG000029 · NIA · DUKE UNIVERSITY · PI Maria Marquine · 1985 to 2026
$9.3M
OLDER BREAST CANCER PATIENTS: RISK FOR COGNITIVE DECLINER01CA129769 · NCI · GEORGETOWN UNIVERSITY · PI AHLES, TIM ALAN, MANDELBLATT, JEANNE · 2009 to 2020
$7.3M
Bio-behavioral Research At The Intersection of Cancer and AgingR35CA197289 · NCI · GEORGETOWN UNIVERSITY · PI MANDELBLATT, JEANNE · 2015 to 2021
$6.2M
Georgetown Lombardi Comprehensive Cancer Center for support of the Biostatistics and Bioinformatics ResourceIndiana Biobank and the Indiana Clinical and Translational Sciences Institute UL1TR002529NCATS NIH HHS UL1 TR002529NCI NIH HHS K01 CA212056NCI NIH HHS K08 CA241337NCI NIH HHS K99 CA270294NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA051008NCI NIH HHS P30 CA082709NCI NIH HHS R00 CA270294NCI NIH HHS R01 CA129769NCI NIH HHS R01 CA172119NCI NIH HHS R01 CA237535NCI NIH HHS R01 CA244673NCI NIH HHS R35 CA197289NCI NIH HHS R35 CA283926NCI NIH HHS U54 CA137788NCRAD Biomarker Assay LabNIA NIH HHS K01 AG065485NIA NIH HHS P30 AG010133NIA NIH HHS P30 AG028716NIA NIH HHS P30 AG072976NIA NIH HHS R01 AG067258NIA NIH HHS R01 AG068193NIA NIH HHS R01 AG082348NIA NIH HHS R56 AG068086NIA NIH HHS T32 AG000029NIA NIH HHS U24 AG021886NIH HHS R01AG068193NIH HHS R01CA129769NINDS NIH HHS R01 NS100704Non-Therapeutic Shared Resource R01CA237535UCLA Cousins Center for Psychoneuroimmunology
6 · The paper itself

Abstract

purposeWe evaluated whether plasma Alzheimer disease (AD)-related biomarkers were associated with cancer-related cognitive decline among older breast cancer survivors.

methodsWe included survivors aged 60-90 years with primary stage 0-III breast cancers (n = 236) and frequency-matched noncancer control paricipant (n = 154) who passed a cognitive screen and had banked plasma specimens. Participants were assessed at baseline (presystemic therapy) and annually for up to 60 months. Cognition was measured using tests of attention, processing speed, and executive function and learning and memory; perceived cognition was measured by the Functional Assessment of Cancer Therapy-Cognitive Function v3 Perceived Cognitive Impairments. Baseline plasma neurofilament light, glial fibrillary acidic protein, β-amyloid 42 and 40 and phosphorylated tau 181 were assayed using single molecule arrays. Mixed models tested associations between cognition and baseline AD biomarkers, time, group (survivor vs control participant), and their 2- and 3-way interactions, controlling for age, race, Wide Range 4 Achievement Test Word Reading score, comorbidity, and body mass index; 2-sided P values of .05 were considered statistically significant.

resultsThere were no group differences in baseline AD-related biomarkers except survivors had higher baseline neurofilament light levels than control participants (P = .013). Survivors had lower adjusted longitudinal attention, processing speed, and executive function than control participants starting from baseline and continuing over time (P ≤ .002). However, baseline AD-related biomarker levels were not independently associated with adjusted cognition over time, except control participants had lower attention, processing speed, and executive function scores with higher glial fibrillary acidic protein levels (P = .008).

conclusionThe results do not support a relationship between baseline AD-related biomarkers and cancer-related cognitive decline. Further investigation is warranted to confirm the findings, test effects of longitudinal changes in AD-related biomarkers, and examine other mechanisms and factors affecting cognition presystemic therapy.

Indexed as

Alzheimer DiseaseBiomarkersBreast NeoplasmsCognitive DysfunctionAgedAged, 80 and overAmyloid beta-PeptidesCancer SurvivorsCase-Control StudiesFemaleGlial Fibrillary Acidic ProteinHumansMiddle AgedNeurofilament ProteinsNeuropsychological Teststau ProteinsAmyloid beta-PeptidesBiomarkersGFAP protein, humanGlial Fibrillary Acidic Proteinneurofilament protein LNeurofilament Proteinstau Proteins

Identifiers

PMID38788675
PMCPMC11378315

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.